The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Some 24 per cent of trial participants receiving the drug experienced brain swelling. Although 75% of people who developed ...

Donanemab (Kisunla) is the first new drug approved in Australia for the treatment of mild cognitive impairment in 25 years.

Australia’s Therapeutic Goods Administration has approved a drug called donanemab for people in the early stages of Alzheimer ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.

Australia's Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer's ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

Australia just approved the first new Alzheimer’s treatment in decades. But before patients get their hopes up, there’s a ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

The first ever drug treatment to target the underlying causes of Alzheimer’s disease has become the first alternative ...